Answers are grounded in this paper and cite their sources.
Osteonecrosis is a major skeletal complication in individuals with sickle cell disease (SCD), yet the biological mechanisms underlying its development remain incompletely understood. Alterations in bone turnover and endocrine regulation have been suggested as potential contributors, highlighting the relevance of biochemical marker assessment. A case–control study was conducted from August 1, 2021, to October 30, 2024, among patients with sickle cell disease (SS and SC phenotypes). The study population comprised 102 patients, including 63 cases with osteonecrosis and 39 controls without osteonecrosis. Assessed markers included parathyroid hormone (PTH), 25-hydroxyvitamin D, osteocalcin (BGP II), Procollagen I N-propeptide (P1NP), Beta-Telopeptide C of procollagen I (β-CTX), calcium, and phosphate. Analyses were performed using the Architect Plus Ci 4100 (Abbott) and Maglumi X6 (Snibe) systems. Statistical analyses were performed using R software version 4.2.3. The median age was 32 ± 11.38 years, with a female predominance (sex ratio: 0.61). PTH levels were significantly lower in patients with osteonecrosis (median 23.1 pg/mL [IQR 46.7]) compared with controls (45 pg/mL [IQR 24.6], p-value = 0.01). Low PTH (<15 pg/mL) was independently associated with osteonecrosis (OR = 12.17; 95% CI: 2.69 to 55.08; p-value:0. 0012). Bone formation markers tended to be lower in AON+ patients without statistical significance. These findings demonstrate that decreased PTH levels are strongly associated with osteonecrosis in SCD, suggesting that endocrine dysregulation may play a key role in its pathophysiology and supporting the integration of targeted biochemical screening into routine clinical follow-up.
No takes yet. Share an insight, caveat, or question.
Pape et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: